A new drug candidate from Bristol-Myers Squibb hits two known cancer targets simultaneously.
At the American Chemical Society annual meeting on Sunday, Ashvinikumar Gavai of Bristol-Myers Squibb described how the drug stops two different types of kinases called HER and VEGFR2 from working.
Laboratory tests on mice showed that it works well on particularly troublesome cancer cells that are resistant to miracle drugs like the breast cancer treatment Herceptin. The drugs is in a Phase I FDA clinical trials.
